{"id":61968,"date":"2025-10-03T13:02:35","date_gmt":"2025-10-03T11:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/"},"modified":"2025-10-03T13:02:35","modified_gmt":"2025-10-03T11:02:35","slug":"eurofins-scientific-director-pdmr-shareholding","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/","title":{"rendered":"Eurofins Scientific: Director\/PDMR Shareholding"},"content":{"rendered":"
\n

LUXEMBOURG–(BUSINESS WIRE)–Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (\u201cPDMR\u201d). The notification of Dealing Form for each PDMR can be found below.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThis notification is made in accordance with the European Market Abuse Regulation.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM<\/b><\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\n1.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the person discharging managerial responsibilities\/person closely associated<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nName<\/p>\n<\/td>\n

\n

\nAnalytical Bioventures S.C.A (RCS B89265)
\n
23, Va Fleuri, L-1526 Luxembourg<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n2.<\/b><\/p>\n<\/td>\n

\n

\nReason for the notification<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nPosition \/ status<\/p>\n<\/td>\n

\n

\nAnalytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nInitial notification \/ amendment<\/p>\n<\/td>\n

\n

\nInitial<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n3.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nName<\/p>\n<\/td>\n

\n

\nEurofins Scientific S.E.<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nLEI<\/p>\n<\/td>\n

\n

\n529900JEHFM47DYY3S57<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n4.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nDescription of the financial instrument, type of instrument<\/p>\n<\/td>\n

\n

\nShare<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nIdentification code<\/p>\n<\/td>\n

\n

\nISIN: FR0014000MR3<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nNature of the transaction<\/p>\n<\/td>\n

\n

\nAcquisition of shares<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nc)<\/p>\n<\/td>\n

\n

\nPrice(s) and volume(s)<\/p>\n<\/td>\n

\n

\nPrice(s)<\/p>\n<\/td>\n

\n

\nVolume(s)<\/p>\n<\/td>\n<\/tr>\n

\n

\nEUR 61.421200<\/p>\n<\/td>\n

\n

\n3000<\/p>\n<\/td>\n<\/tr>\n

\n

\nd)<\/p>\n<\/td>\n

\n

\nAggregated information<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u2014 Aggregated volume<\/p>\n<\/td>\n

\n

\n3000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

\n\u2014 Price<\/p>\n<\/td>\n

\n

\nEUR 184,263.60<\/p>\n<\/td>\n<\/tr>\n

\n

\ne)<\/p>\n<\/td>\n

\n

\nDate of the transaction<\/p>\n<\/td>\n

\n

\n2025-09-29<\/p>\n<\/td>\n<\/tr>\n

\n

\nf)<\/p>\n<\/td>\n

\n

\nPlace of the transaction<\/p>\n<\/td>\n

\n

\nXPAR<\/p>\n<\/td>\n<\/tr>\n

\n

\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM<\/b><\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\n1.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the person discharging managerial responsibilities\/person closely associated<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nName<\/p>\n<\/td>\n

\n

\nAnalytical Bioventures S.C.A (RCS B89265)
\n
23, Va Fleuri, L-1526 Luxembourg<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n2.<\/b><\/p>\n<\/td>\n

\n

\nReason for the notification<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nPosition \/ status<\/p>\n<\/td>\n

\n

\nAnalytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nInitial notification \/ amendment<\/p>\n<\/td>\n

\n

\nInitial<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n3.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nName<\/p>\n<\/td>\n

\n

\nEurofins Scientific S.E.<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nLEI<\/p>\n<\/td>\n

\n

\n529900JEHFM47DYY3S57<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n4.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nDescription of the financial instrument, type of instrument<\/p>\n<\/td>\n

\n

\nShare<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nIdentification code<\/p>\n<\/td>\n

\n

\nISIN: FR0014000MR3<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nNature of the transaction<\/p>\n<\/td>\n

\n

\nAcquisition of shares<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nc)<\/p>\n<\/td>\n

\n

\nPrice(s) and volume(s)<\/p>\n<\/td>\n

\n

\nPrice(s)<\/p>\n<\/td>\n

\n

\nVolume(s)<\/p>\n<\/td>\n<\/tr>\n

\n

\nEUR 60.840600<\/p>\n<\/td>\n

\n

\n3000<\/p>\n<\/td>\n<\/tr>\n

\n

\nd)<\/p>\n<\/td>\n

\n

\nAggregated information<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u2014 Aggregated volume<\/p>\n<\/td>\n

\n

\n3000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

\n\u2014 Price<\/p>\n<\/td>\n

\n

\nEUR 182,521.80<\/p>\n<\/td>\n<\/tr>\n

\n

\ne)<\/p>\n<\/td>\n

\n

\nDate of the transaction<\/p>\n<\/td>\n

\n

\n2025-09-30<\/p>\n<\/td>\n<\/tr>\n

\n

\nf)<\/p>\n<\/td>\n

\n

\nPlace of the transaction<\/p>\n<\/td>\n

\n

\nXPAR<\/p>\n<\/td>\n<\/tr>\n

\n

\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM<\/b><\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/tr>\n
\n

\n1.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the person discharging managerial responsibilities\/person closely associated<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nName<\/p>\n<\/td>\n

\n

\nAnalytical Bioventures S.C.A (RCS B89265)
\n
23, Va Fleuri, L-1526 Luxembourg<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n2.<\/b><\/p>\n<\/td>\n

\n

\nReason for the notification<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nPosition \/ status<\/p>\n<\/td>\n

\n

\nAnalytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nInitial notification \/ amendment<\/p>\n<\/td>\n

\n

\nInitial<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n3.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nName<\/p>\n<\/td>\n

\n

\nEurofins Scientific S.E.<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nLEI<\/p>\n<\/td>\n

\n

\n529900JEHFM47DYY3S57<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n4.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nDescription of the financial instrument, type of instrument<\/p>\n<\/td>\n

\n

\nShare<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nIdentification code<\/p>\n<\/td>\n

\n

\nISIN: FR0014000MR3<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nNature of the transaction<\/p>\n<\/td>\n

\n

\nAcquisition of shares<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nc)<\/p>\n<\/td>\n

\n

\nPrice(s) and volume(s)<\/p>\n<\/td>\n

\n

\nPrice(s)<\/p>\n<\/td>\n

\n

\nVolume(s)<\/p>\n<\/td>\n<\/tr>\n

\n

\nEUR 62.779900<\/p>\n<\/td>\n

\n

\n3000<\/p>\n<\/td>\n<\/tr>\n

\n

\nd)<\/p>\n<\/td>\n

\n

\nAggregated information<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u2014 Aggregated volume<\/p>\n<\/td>\n

\n

\n3000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

\n\u2014 Price<\/p>\n<\/td>\n

\n

\nEUR 188,339.70<\/p>\n<\/td>\n<\/tr>\n

\n

\ne)<\/p>\n<\/td>\n

\n

\nDate of the transaction<\/p>\n<\/td>\n

\n

\n2025-10-01<\/p>\n<\/td>\n<\/tr>\n

\n

\nf)<\/p>\n<\/td>\n

\n

\nPlace of the transaction<\/p>\n<\/td>\n

\n

\nXPAR<\/p>\n<\/td>\n<\/tr>\n

\n

\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n1.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the person discharging managerial responsibilities\/person closely associated<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nName<\/p>\n<\/td>\n

\n

\nAnalytical Bioventures S.C.A (RCS B89265)
\n
23, Va Fleuri, L-1526 Luxembourg<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n2.<\/b><\/p>\n<\/td>\n

\n

\nReason for the notification<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nPosition \/ status<\/p>\n<\/td>\n

\n

\nAnalytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nInitial notification \/ amendment<\/p>\n<\/td>\n

\n

\nInitial<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n3.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nName<\/p>\n<\/td>\n

\n

\nEurofins Scientific S.E.<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nLEI<\/p>\n<\/td>\n

\n

\n529900JEHFM47DYY3S57<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/tr>\n
\n

\n4.<\/b><\/p>\n<\/td>\n

\n

\nDetails of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\na)<\/p>\n<\/td>\n

\n

\nDescription of the financial instrument, type of instrument<\/p>\n<\/td>\n

\n

\nShare<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nIdentification code<\/p>\n<\/td>\n

\n

\nISIN: FR0014000MR3<\/p>\n<\/td>\n<\/tr>\n

\n

\nb)<\/p>\n<\/td>\n

\n

\nNature of the transaction<\/p>\n<\/td>\n

\n

\nAcquisition of shares<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nc)<\/p>\n<\/td>\n

\n

\nPrice(s) and volume(s)<\/p>\n<\/td>\n

\n

\nPrice(s)<\/p>\n<\/td>\n

\n

\nVolume(s)<\/p>\n<\/td>\n<\/tr>\n

\n

\nEUR 62.992000<\/p>\n<\/td>\n

\n

\n3000<\/p>\n<\/td>\n<\/tr>\n

\n

\nd)<\/p>\n<\/td>\n

\n

\nAggregated information<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u2014 Aggregated volume<\/p>\n<\/td>\n

\n

\n3000<\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

\n\u2014 Price<\/p>\n<\/td>\n

\n

\nEUR 188,976.00<\/p>\n<\/td>\n<\/tr>\n

\n

\ne)<\/p>\n<\/td>\n

\n

\nDate of the transaction<\/p>\n<\/td>\n

\n

\n2025-10-02<\/p>\n<\/td>\n<\/tr>\n

\n

\nf)<\/p>\n<\/td>\n

\n

\nPlace of the transaction<\/p>\n<\/td>\n

\n

\nXPAR<\/p>\n<\/td>\n<\/tr>\n

\n

\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout Eurofins \u2013 the global leader in bio-analysis<\/b><\/p>\n

\nEurofins is Testing for Life. With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods.<\/p>\n

\nEurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information, please visit <\/b>www.eurofins.com<\/a> or contact:<\/b><\/p>\n

Investor Relations
\n
Eurofins Scientific SE
\n
Phone: +32 2 766 1620
\n
E-mail: ir@sc.eurofinseu.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LUXEMBOURG–(BUSINESS WIRE)–Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (\u201cPDMR\u201d). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61968","6":"format-standard","7":"category-industry"},"yoast_head":"\nEurofins Scientific: Director\/PDMR Shareholding - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eurofins Scientific: Director\/PDMR Shareholding - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LUXEMBOURG–(BUSINESS WIRE)–Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (\u201cPDMR\u201d). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-03T11:02:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251003141981\/en\/2477928\/22\/EUROFINS_jpg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Eurofins Scientific: Director\\\/PDMR Shareholding\",\"datePublished\":\"2025-10-03T11:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/\"},\"wordCount\":876,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251003141981\\\/en\\\/2477928\\\/22\\\/EUROFINS_jpg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/\",\"name\":\"Eurofins Scientific: Director\\\/PDMR Shareholding - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251003141981\\\/en\\\/2477928\\\/22\\\/EUROFINS_jpg.jpg\",\"datePublished\":\"2025-10-03T11:02:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251003141981\\\/en\\\/2477928\\\/22\\\/EUROFINS_jpg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251003141981\\\/en\\\/2477928\\\/22\\\/EUROFINS_jpg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eurofins-scientific-director-pdmr-shareholding\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eurofins Scientific: Director\\\/PDMR Shareholding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eurofins Scientific: Director\/PDMR Shareholding - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/","og_locale":"en_US","og_type":"article","og_title":"Eurofins Scientific: Director\/PDMR Shareholding - Pharma Trend","og_description":"LUXEMBOURG–(BUSINESS WIRE)–Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (\u201cPDMR\u201d). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-03T11:02:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251003141981\/en\/2477928\/22\/EUROFINS_jpg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Eurofins Scientific: Director\/PDMR Shareholding","datePublished":"2025-10-03T11:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/"},"wordCount":876,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251003141981\/en\/2477928\/22\/EUROFINS_jpg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/","url":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/","name":"Eurofins Scientific: Director\/PDMR Shareholding - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251003141981\/en\/2477928\/22\/EUROFINS_jpg.jpg","datePublished":"2025-10-03T11:02:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251003141981\/en\/2477928\/22\/EUROFINS_jpg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251003141981\/en\/2477928\/22\/EUROFINS_jpg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/eurofins-scientific-director-pdmr-shareholding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Eurofins Scientific: Director\/PDMR Shareholding"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61968"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61968\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}